ClinCalc Pro
Menu
CDK4/6 inhibitor

Palbociclib (Specialist drug)

Brand names: Ibrance

Adult dose

Dose: Specialist initiation only — refer to BNF/SmPC
Route: PO
Frequency: OD x 21 days q28

Clinical pearls

  • HR+ HER2- advanced breast cancer with endocrine therapy
  • FBC every 2 weeks for first 2 cycles, then before each cycle

Contraindications

  • Concurrent strong CYP3A4 inducers
  • Severe hepatic impairment

Side effects

  • Severe neutropenia (most common dose-limiting AE)
  • Pulmonary embolism / VTE
  • Pneumonitis
  • Stomatitis
  • Hepatotoxicity

Interactions

  • Strong CYP3A4 modulators
  • Drugs raising gastric pH

Monitoring

  • FBC
  • LFTs
  • Pulmonary symptoms

Reference: BNF; NICE TA495; SmPC; https://bnf.nice.org.uk/drugs/palbociclib-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.